42463-41-2

Usage

Uses

Used in Pharmaceutical Industry:
2(1H)-Pyridinone,3-(hydroxymethyl)-(9CI) is used as a pharmaceutical intermediate for the development of drugs that can potentially harness its antioxidant and radioprotector properties. Its ability to form hydrogen bonds may also contribute to the design of new therapeutic agents.
Used in Medical Industry:
In the medical field, 2(1H)-Pyridinone,3-(hydroxymethyl)-(9CI) is utilized for its potential therapeutic properties, which include its antioxidant and radioprotector activities. These characteristics may be beneficial in the treatment or prevention of conditions associated with oxidative stress or radiation exposure.

InChI:InChI=1/C6H7NO2/c8-4-5-2-1-3-7-6(5)9/h1-3,8H,4H2,(H,7,9)

Upstream product

• 609-71-2 2-hydroxy-3-carboxypyridine 
• 49609-84-9 2-Chloronicotinoyl chloride 
• 2942-59-8 2-chloronicotinic acid 
• 67367-26-4 2-methoxynicotinic acid methyl ester 
• 40134-18-7 methyl 2-chloropyridine-3-carboxylate 
• 112197-16-7 (2-methoxy-pyridin-3-yl)-methanol 
• 1450-14-2 1,1,1,2,2,2-hexamethyldisilane 
• 183274-22-8 trimethylsilyl 2-(trimethylsilyloxy)nicotinate 

Downstream Products

• 36721-61-6 3-(hydroxymethyl)-1-methylpyridin-2(1H)-one 
• 51417-15-3 3-(chloromethyl)-1-methylpyridin-2(1H)-one 
• 36404-89-4 2-hydroxy-3-pyridinecarboxaldehyde 
• 1093183-14-2 3-({[tert-Butyl(diphenyl)silyl]oxy}methyl)pyridin-2(1H)-one 

Relevant academic research and scientific papers

Development of oxathiino[6,5-b]pyridine 2,2-dioxide derivatives as selective inhibitors of tumor-related carbonic anhydrases IX and XII

Oxathiino[6,5-b]pyridine 2,2-dioxides are identified as a new class of isoform-selective nanomolar inhibitors of tumor associated human carbonic anhydrases (hCA) IX and XII. At the same time they do not inhibit or poorly inhibit cytosolic isoforms hCA I and II. Oxathiino[6,5-b]pyridine 2,2-dioxides exhibited good antiproliferative properties on tumor cell lines MCF-7 (Human breast adenocarcinoma), A549 (human lung (alveolar) adenocarcinoma) and HeLa (epithelioid cervix carcinoma).

SUBSTITUTED OXAZOLIDINONES AND THEIR USE

The invention relates to novel substituted oxazolidinones, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of thromboembolic disorders.

SUBSTITUTED OXAZOLIDINONES AND THEIR USE

The invention relates to novel substituted oxazolidinones, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in parti

ANTIPRURITICS

It is intended to provide antipruritics (drugs to control itching, antiitch agents and drugs to stop itching). It is found out that a compound having an agonistic activity to the cannabinoid receptor shows an antipruritics effect.

PYRIDONE DERIVATIVE HAVING AFFINITY FOR CANNABINOID 2-TYPE RECEPTOR

It was found that the compound having a binding activity to the cannabinoid type 2 receptor represented by the formula (I): wherein R' is a group represented by the formula: -Y1-Y2-Y3Ra wherein Y1 is single bond or the like; Y2 is -C(=O)-NH- or the like; Y3 is optionally substituted aryl or the like; R2 is hydrogen or the like; R3 is alkyl or the like; R4 is alkyl or the like; R5 is optionally substituted alkyl or the like; or R3 and R4 taken together with the adjacent atom form cyclic group or the like.

Tether-enforced reversal of regioselectivity: Head-to-head [4 + 4] photocycloaddition of 2-pyridones

Symmetric 3,3′-attachment of a three-atom chain between two pyridones overrides the head-to-tail regioselectivity found in intermolecular photodimerization reactions and gives a nearly quantitative yield of the head-to-head [4 + 4] cycloadduct containing contiguous quaternary centres.

Syntheses of ortho-hydroxymethylpyridinols and dioxaphosphorino[m,n-x]pyridines

Dioxaphosphorino[m,n-x]pyridines compounds have been prepared by condensation of methyl dichlorophosphate with new ortho-hydroxymethylpyridinols.